Wall Street analysts predict that Achaogen, Inc. (NASDAQ:AKAO) will report ($0.72) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Achaogen’s earnings. The lowest EPS estimate is ($0.81) and the highest is ($0.62). Achaogen posted earnings of ($0.41) per share in the same quarter last year, which would suggest a negative year over year growth rate of 75.6%. The firm is scheduled to announce its next quarterly earnings results on Monday, November 6th.
According to Zacks, analysts expect that Achaogen will report full year earnings of ($2.99) per share for the current fiscal year, with EPS estimates ranging from ($3.50) to ($2.70). For the next financial year, analysts forecast that the company will report earnings of ($2.73) per share, with EPS estimates ranging from ($3.32) to ($2.00). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Achaogen.
Achaogen (NASDAQ:AKAO) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.18). Achaogen had a negative return on equity of 86.24% and a negative net margin of 281.88%. The firm had revenue of $1.30 million for the quarter, compared to the consensus estimate of $2.69 million. During the same period in the prior year, the business earned ($0.87) EPS. The company’s quarterly revenue was down 85.7% on a year-over-year basis.
A number of equities research analysts recently weighed in on the company. Mizuho assumed coverage on Achaogen in a research report on Wednesday, September 6th. They set a “buy” rating and a $28.00 target price on the stock. BidaskClub raised Achaogen from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 22nd. Stifel Nicolaus reissued a “buy” rating and set a $30.00 target price on shares of Achaogen in a research report on Friday, August 4th. Zacks Investment Research raised Achaogen from a “sell” rating to a “hold” rating and set a $27.00 target price on the stock in a research report on Monday, July 17th. Finally, HC Wainwright assumed coverage on Achaogen in a research report on Thursday, June 15th. They set a “buy” rating and a $29.00 target price on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. Achaogen currently has an average rating of “Buy” and an average target price of $26.07.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new stake in Achaogen during the second quarter valued at approximately $168,000. Bank of Montreal Can boosted its holdings in Achaogen by 25.0% during the first quarter. Bank of Montreal Can now owns 7,500 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 1,500 shares in the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in Achaogen during the first quarter valued at approximately $199,000. Sigma Planning Corp boosted its holdings in Achaogen by 9.6% during the second quarter. Sigma Planning Corp now owns 9,450 shares of the biopharmaceutical company’s stock valued at $205,000 after purchasing an additional 825 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Achaogen by 691.2% during the second quarter. JPMorgan Chase & Co. now owns 11,077 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 9,677 shares in the last quarter. 84.12% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/09/18/achaogen-inc-akao-expected-to-post-earnings-of-0-72-per-share.html.
Achaogen (NASDAQ:AKAO) traded up 1.364% on Friday, reaching $16.715. The company’s stock had a trading volume of 426,401 shares. The stock’s 50 day moving average is $18.01 and its 200-day moving average is $21.79. The firm’s market capitalization is $705.92 million. Achaogen has a 52 week low of $3.68 and a 52 week high of $27.79.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.